FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 18,400 shares of the business’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $46.81, for a total transaction of $861,304.00. Following the transaction, the chief executive officer now owns 2,550,176 shares in the company, valued at $119,373,738.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ:FGEN opened at $47.21 on Friday. The company has a current ratio of 7.75, a quick ratio of 7.75 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $4.04 billion, a price-to-earnings ratio of -45.83 and a beta of 1.72. FibroGen Inc has a 1-year low of $37.27 and a 1-year high of $68.55.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Wednesday, February 27th. The biopharmaceutical company reported $0.23 earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.40. The company had revenue of $108.05 million for the quarter, compared to analyst estimates of $72.15 million. FibroGen had a negative net margin of 40.58% and a negative return on equity of 16.84%. FibroGen’s revenue was up 251.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.27) EPS. Equities analysts expect that FibroGen Inc will post -0.97 EPS for the current fiscal year.

A number of research firms recently weighed in on FGEN. Zacks Investment Research upgraded shares of FibroGen from a “hold” rating to a “buy” rating and set a $52.00 price target on the stock in a research report on Tuesday, January 8th. BidaskClub upgraded shares of FibroGen from a “hold” rating to a “buy” rating in a research report on Saturday, December 22nd. Piper Jaffray Companies began coverage on shares of FibroGen in a research report on Friday, April 12th. They set a “neutral” rating and a $65.00 price target on the stock. TheStreet upgraded shares of FibroGen from a “d+” rating to a “c-” rating in a research report on Friday, March 29th. Finally, ValuEngine lowered shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. FibroGen currently has a consensus rating of “Buy” and an average target price of $71.17.

A number of large investors have recently bought and sold shares of the business. American International Group Inc. boosted its holdings in FibroGen by 1.0% in the 4th quarter. American International Group Inc. now owns 50,074 shares of the biopharmaceutical company’s stock valued at $2,317,000 after purchasing an additional 478 shares during the last quarter. BBR Partners LLC boosted its holdings in FibroGen by 7.6% in the 4th quarter. BBR Partners LLC now owns 7,056 shares of the biopharmaceutical company’s stock valued at $327,000 after purchasing an additional 500 shares during the last quarter. Meeder Asset Management Inc. boosted its holdings in FibroGen by 622.4% in the 4th quarter. Meeder Asset Management Inc. now owns 614 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 529 shares during the last quarter. Chartwell Investment Partners LLC boosted its holdings in FibroGen by 1.4% in the 1st quarter. Chartwell Investment Partners LLC now owns 44,073 shares of the biopharmaceutical company’s stock valued at $2,395,000 after purchasing an additional 598 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in FibroGen by 13.1% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,259 shares of the biopharmaceutical company’s stock valued at $243,000 after purchasing an additional 609 shares during the last quarter. Institutional investors own 66.58% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Thomas B. Neff Sells 18,400 Shares of FibroGen Inc (FGEN) Stock” was posted by Marea Informative and is the sole property of of Marea Informative. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.mareainformativa.com/news/2019/04/21/thomas-b-neff-sells-18400-shares-of-fibrogen-inc-fgen-stock.html.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Recommended Story: How to interpret the current ratio

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.